|
NASH | Abstract Library |
 |
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
1. | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis |
|
Gut. 2023 Mar;72(3):581-589. doi: 10.1136/gutjnl-2022-327777. Epub 2022 Sep 9.
Rohit Loomba 1 2, Daniel Q Huang 2 3 4, Arun J Sanyal 5, Quentin Mark Anstee 6, Michael Trauner 7, Eric J Lawitz 8, Dora Ding 9, Lily Ma 9, Catherine Jia 9, Andrew Billin 9, Ryan S Huss 9, Chuhan Chung 9, Zachary Goodman 10, Vincent Wai-Sun Wong 11, Takeshi Okanoue 12, Manuel Romero-Gómez 13, Manal F Abdelmalek 14, Andrew Muir 15, Nezam Afdhal 16, Jaime Bosch 17, Stephen Harrison 18 19, Zobair M Younossi 20, Robert P Myers 9
|
|
|
2. | Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants |
|
Am J Gastroenterol. 2023 Apr 1;118(4):645-653.doi: 10.14309/ajg.0000000000002042. Epub 2022 Sep 30.
Phoebe Wen Lin Tay 1, Cheng Han Ng 1, Snow Yunni Lin 1, Yip Han Chin 1, Jieling Xiao 1, Wen Hui Lim 1, Sze Yinn Lim 1, Clarissa Elysia Fu 1, Kai En Chan 1, Jingxuan Quek 1, Darren Jun Hao Tan 1, Nicholas Chew 2, Nicholas Syn 1, Taisei Keitoku 3, Nobuharu Tamaki 3, Mohammad Shadab Siddiqui 4, Mazen Noureddin 5, Mark Muthiah 1 6 7, Daniel Q Huang 1 6 7, Rohit Loomba 8
|
|
|
|
|
|
|
|
|
|
|
7. | Associations between an inflammatory diet index and severe non-alcoholic fatty liver disease: a prospective study of 171,544 UK Biobank participants |
|
BMC Med. 2023 Apr 3;21(1):123. doi: 10.1186/s12916-023-02793-y.
Fanny Petermann-Rocha 1 2, Michael D Wirth 3 4, Jirapitcha Boonpor 1 5, Solange Parra-Soto 1 6, Ziyi Zhou 7, John C Mathers 8, Katherine Livingstone 9, Ewan Forrest 10, Jill P Pell 7, Frederick K Ho 7, James R Hébert 4, Carlos Celis-Morales 11 12
|
|
|
|
|
|
|
|
|
11. | Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial |
|
Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522.doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16.
Rohit Loomba 1, Manal F Abdelmalek 2, Matthew J Armstrong 3, Maximilian Jara 4, Mette Skalshøi Kjær 4, Niels Krarup 4, Eric Lawitz 5, Vlad Ratziu 6, Arun J Sanyal 7, Jörn M Schattenberg 8, Philip N Newsome 3; NN9931-4492 investigators
|
|
|
|
|
13. | American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease |
|
Hepatol Commun. 2023 Mar 30;7(4):e0108. doi: 10.1097/HC9.0000000000000108.eCollection 2023 Apr 1.
Jonathan G Stine 1 2, Michelle T Long 3, Kathleen E Corey 4, Robert E Sallis 5, Alina M Allen 6, Matthew J Armstrong 7, David E Conroy 8, Daniel J Cuthbertson 9, Andres Duarte-Rojo 10, Kate Hallsworth 11, Ingrid J Hickman 12, Matthew R Kappus 13, Shelley E Keating 14, Christopher J A Pugh 15, Yaron Rotman 16, Tracey G Simon 4, Eduardo Vilar-Gomez 17, Vincent Wai-Sun Wong 18, Kathryn H Schmitz 2
|
|
|
|
|
15. | Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease |
|
J Hepatol. 2023 Apr;78(4):693-703. doi: 10.1016/j.jhep.2022.11.029.Epub 2022 Dec 14.
Arun J Sanyal 1, Stephen A Williams 2, Joel E Lavine 3, Brent A Neuschwander-Tetri 4, Leigh Alexander 5, Rachel Ostroff 2, Hannah Biegel 5, Kris V Kowdley 6, Naga Chalasani 7, Srinivasan Dasarathy 8, Anna Mae Diehl 9, Rohit Loomba 10, Bilal Hameed 11, Cynthia Behling 10, David E Kleiner 12, Saul J Karpen 13, Jessica Williams 14, Yi Jia 2, Katherine P Yates 15, James Tonascia 15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23. | NAFLD and NASH Biomarker Qualification in the LITMUS consortium - Lessons learned |
|
Hepatol. 2022 Dec 13;S0168-8278(22)03325-6. doi: 10.1016/j.jhep.2022.11.028.Online ahead of print.
Daniel Guldager Kring Rasmussen 1, Quentin M Anstee 2, Richard Torstenson 3, Bruno Golding 4, Scott D Patterson 5, Clifford Brass 6, Paresh Thakker 7, Stephen Harrison 8, Andrew N Billin 5, Detlef Schuppan 9, Jean-François Dufour 10, Anneli Andersson 11, Ioan Wigley 11, Elizabeth Shumbayawonda 11, Andrea Dennis 11, Corinna Schoelch 12, Vlad Ratziu 13, Carla Yunis 14, Patrick Bossuyt 15, Morten Asser Karsdal 16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32. | The nonalcoholic steatohepatitis extended hepatocyte ballooning score: histologic classification and clinical significance |
|
Hepatol Commun. 2023 Feb 1;7(2):e0033. doi: 10.1097/HC9.0000000000000033.
Ryan M Gill 1, Daniela Allende 2, Patricia H Belt 3, Cynthia A Behling 4, Oscar W Cummings 5, Cynthia D Guy 6, Daniela Carpenter 7, Brent A Neuschwander-Tetri 8, Arun J Sanyal 9, James Tonascia 3, Mark L Van Natta 3, Laura A Wilson 3, Goro Yamada 3, Matthew Yeh 10, David E Kleiner 11; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)
|
|
|
|
|
|
|
|
|
36. | The Effects of Eight Weeks' Very Low-Calorie Ketogenic Diet (VLCKD) on Liver Health in Subjects Affected by Overweight and Obesity |
|
Nutrients. 2023 Feb 6;15(4):825. doi: 10.3390/nu15040825.
Roberta Rinaldi 1, Sara De Nucci 1, Fabio Castellana 2, Martina Di Chito 1, Vito Giannuzzi 3, Endrit Shahini 3, Roberta Zupo 2, Luisa Lampignano 2, Giuseppina Piazzolla 4, Vincenzo Triggiani 4, Raffaele Cozzolongo 3, Gianluigi Giannelli 5, Giovanni De Pergola 1
|
|
|
|
|
|
|
|
|
|
|
41. | Review article: The need for more efficient and patient-oriented drug development pathways in NASH-setting the scene for platform trials |
|
Aliment Pharmacol Ther. 2023 May;57(9):948-961. doi: 10.1111/apt.17456.Epub 2023 Mar 14.
Juan M Pericàs 1, Nicholas A Di Prospero 2, Quentin M Anstee 3 4, Peter Mesenbrinck 5, Mette S Kjaer 6, Jesús Rivera-Esteban 1, Franz Koenig 7, Elena Sena 1, Raluca Pais 8, Ramiro Manzano 1, Joan Genescà 1, Frank Tacke 9, Vlad Ratziu 8; EU-PEARL NASH Investigators
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
56. | Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis |
|
Hepatology. 2023 Feb 1;77(2):546-557. doi: 10.1002/hep.32655. Epub 2022 Aug 9.
Devon Chang 1, Emily Truong 2, Edward A Mena 3, Fabiana Pacheco 3, Micaela Wong 3, Maha Guindi 4, Tsuyoshi T Todo 5, Nabil Noureddin 6, Walid Ayoub 2 5 7, Ju Dong Yang 2 5 7, Irene K Kim 5, Anita Kohli 8, Naim Alkhouri 8, Stephen Harrison 9, Mazen Noureddin 2 5 7
|
|
|
|
|
58. | Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores |
|
J Hepatol. 2023 Feb;78(2):247-259. doi: 10.1016/j.jhep.2022.10.034. Epub 2022 Nov 12.
Arun J Sanyal 1, Julie Foucquier 2, Zobair M Younossi 3, Stephen A Harrison 4, Philip N Newsome 5, Wah-Kheong Chan 6, Yusuf Yilmaz 7, Victor De Ledinghen 8, Charlotte Costentin 9, Ming-Hua Zheng 10, Vincent Wai-Sun Wong 11, Magdy Elkhashab 12, Ryan S Huss 13, Robert P Myers 13, Marine Roux 14, Aymeric Labourdette 2, Marie Destro 2, Céline Fournier-Poizat 15, Véronique Miette 2, Laurent Sandrin 2, Jérôme Boursier 16
|
|
|
59. | A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes |
|
J Hepatol. 2023 Mar;78(3):471-478. doi: 10.1016/j.jhep.2022.11.010. Epub 2022 Nov 19.
Veeral Ajmera 1, Sandra Cepin 2, Kaleb Tesfai 2, Heather Hofflich 3, Karen Cadman 4, Scarlett Lopez 2, Egbert Madamba 2, Ricki Bettencourt 2, Lisa Richards 2, Cynthia Behling 5, Claude B Sirlin 6, Rohit Loomba 7
|
|
|
60. | Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial |
|
Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8.Epub 2023 Feb 16.
Arun J Sanyal 1, Patricia Lopez 2, Eric J Lawitz 3, Kathryn J Lucas 4, Juergen Loeffler 2, Won Kim 5, George B B Goh 6, Jee-Fu Huang 7, Carla Serra 8, Pietro Andreone 9 10, Yi-Cheng Chen 11, Stanley H Hsia 12, Vlad Ratziu 13, Diego Aizenberg 14, Hiroshi Tobita 15, Aasim M Sheikh 16, John M Vierling 17, Yoon Jun Kim 18, Hideyuki Hyogo 19 20, Dean Tai 21, Zachary Goodman 22, Felicity Schaefer 23, Ian R I Carbarns 2, Sophie Lamle 2, Miljen Martic 2, Nikolai V Naoumov 2, Clifford A Brass 23
|
|
|
61. | Mobile health lifestyle intervention program leads to clinically significant loss of body weight in patients with NASH |
|
Hepatol Commun. 2023 Mar 17;7(4):e0052.doi: 10.1097/HC9.0000000000000052. eCollection 2023 Apr 1.
Jonathan G Stine 1 2 3 4, Gloriany Rivas 1, Breianna Hummer 1, Andres Duarte-Rojo 5, Christine N May 6, Nathaniel Geyer 2, Vernon M Chinchilli 2, David E Conroy 7, Ellen Siobhan Mitchell 6, Meaghan McCallum 6, Andreas Michealides 6, Kathryn H Schmitz 4 7 8
|
|
|
|
|
63. | Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis |
|
J Hepatol. 2023 Feb;78(2):238-246.doi: 10.1016/j.jhep.2022.10.027. Epub 2022 Nov 8.
Wei Shen 1, Michael S Middleton 2, Guilherme M Cunha 3, Timoteo I Delgado 2, Tanya Wolfson 4, Anthony Gamst 5, Kathryn J Fowler 2, Adina Alazraki 6, Andrew T Trout 7, Michael A Ohliger 8, Shetal N Shah 9, Mustafa R Bashir 10, David E Kleiner 11, Rohit Loomba 12, Brent A Neuschwander-Tetri 13, Arun J Sanyal 14, Jane Zhou 15, Claude B Sirlin 2, Joel E Lavine 16
|
|
|
|
|
65. | A prolonged fast improves overnight substrate oxidation without modulating hepatic glycogen in adults with and without nonalcoholic fatty liver: A randomized crossover trial |
|
Obesity (Silver Spring). 2023 Mar;31(3):757-767.doi: 10.1002/oby.23676. Epub 2023 Feb 9.
Kay H M Roumans 1, Anna Veelen 1, Charlotte Andriessen 1, Julian Mevenkamp 1 2, Esther Kornips 1, Pandichelvam Veeraiah 1 2, Bas Havekes 1 3, Harry P F Peters 4, Lucas Lindeboom 1 2, Patrick Schrauwen 1, Vera B Schrauwen-Hinderling 1 2 5
|
|
|
66. | An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD |
|
Clin Gastroenterol Hepatol. 2023 Mar;21(3):619-629.e7.doi: 10.1016/j.cgh.2021.11.038. Epub 2021 Dec 4.
Grace En Hui Lim 1, Ansel Tang 2, Cheng Han Ng 2, Yip Han Chin 2, Wen Hui Lim 2, Darren Jun Hao Tan 2, Jie Ning Yong 2, Jieling Xiao 2, Chloe Wen-Min Lee 2, Mark Chan 3, Nicholas Ws Chew 4, Eunice Xiang Xuan Tan 5, Mohammad Shadab Siddiqui 6, Daniel Huang 5, Mazen Noureddin 7, Arun J Sanyal 6, Mark D Muthiah 8
|
|
|
|
|
68. | Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP) |
|
Pharmacol Res. 2023 Mar;189:106679. doi: 10.1016/j.phrs.2023.106679.Epub 2023 Feb 8.
Manfredi Rizzo 1, Alessandro Colletti 2, Peter E Penson 3, Niki Katsiki 4, Dimitri P Mikhailidis 5, Peter P Toth 6, Ioanna Gouni-Berthold 7, John Mancini 8, David Marais 9, Patrick Moriarty 10, Massimiliano Ruscica 11, Amirhossein Sahebkar 12, Dragos Vinereanu 13, Arrigo Francesco Giuseppe Cicero 14, Maciej Banach 15; International Lipid Expert Panel (ILEP)
|
|
|
|
|
|
|
|
|
|
|
73. | Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium |
|
Clin Gastroenterol Hepatol. 2023 Feb;21(2):445-455.e2. doi: 10.1016/j.cgh.2022.02.028.Epub 2022 Feb 18.
Mary E Rinella 1, Sanjaya K Satapathy 2, Danielle Brandman 3, Coleman Smith 4, Sal Elwir 5, Jonathan Xia 6, Meg Gibson 6, Carlos Figueredo 7, Mounika Angirekula 8, Jason M Vanatta 9, Raiya Sarwar 10, Yu Jiang 9, Dyanna Gregory 6, Tandy Agostini 4, JimIn Ko 4, Pradeep Podila 11, Grace Gallo 6, Kymberly D Watt 8, Mohammad S Siddiqui 12
|
|
|
|
|
75. | Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies |
|
Oncologist. 2023 Feb 10;oyac251. doi: 10.1093/oncolo/oyac251. Online ahead of print.
Surendra Pal Chaudhary 1, Stephanie Reyes 2, Matthew L Chase 3, Aparna Govindan 4, Lei Zhao 5, Jay Luther 6, Irun Bhan 6, Emily Bethea 6, Joseph W Franses 1, Elizabeth Paige Walsh 1, Leigh Anne Dageford 7, Shoko Kimura 7, Nahel Elias 7, Heidi Yeh 7, James Markman 7, Adel Bozorgzadeh 7, Kenneth Tanabe 8, Cristina Ferrone 8, Andrew X Zhu 9, Karin Andersson 6, Michael Thiim 6, Onofrio Antonio Catalano 10, Avinash Kambadakone 10, Parsia A Vagefi 11, Motaz Qadan 8, Daniel Pratt 6, Nikroo Hashemi 12, Kathleen E Corey 6, Joseph Misdraji 13, Lipika Goyal 1, Jeffrey W Clark 1
|
|
|
76. | Cardiovascular Morbidity and Mortality Related to Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis |
|
Curr Probl Cardiol. 2023 Feb 10;48(6):101643. doi: 10.1016/j.cpcardiol.2023.101643.Online ahead of print.
Giandomenico Bisaccia 1, Fabrizio Ricci 2, Mohammed Y Khanji 3, Anna Sorella 1, Eugenia Melchiorre 1, Giovanni Iannetti 1, Kristian Galanti 1, Cesare Mantini 1, Andrea Delli Pizzi 4, Claudio Tana 5, Giulia Renda 1, Artur Fedorowski 6, Raffaele De Caterina 7, Sabina Gallina 1
|
|
|
|
|
|
|
79. | Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population-based study and review of literature |
|
J Gastroenterol Hepatol. 2023 Feb;38(2):269-273. doi: 10.1111/jgh.16049.Epub 2022 Nov 16.
Ashraf Almomani 1, Prabhat Kumar 1, Somtochukwu Onwuzo 1, Antoine Boustany 1, Eduard Krishtopaytis 1, Asif Hitawala 2, Dana Alshaikh 3, Almaza Albakri 4, Leen Hussein 5, Ebrahim Hussein 5, Imad Asaad 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
87. | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat |
|
Clin Gastroenterol Hepatol. 2023 Jan;21(1):143-152.e3.doi: 10.1016/j.cgh.2021.12.044. Epub 2022 Jan 6.
Eric J Lawitz 1, Bal Raj Bhandari 2, Peter J Ruane 3, Anita Kohli 4, Eliza Harting 5, Dora Ding 5, Jen-Chieh Chuang 5, Ryan S Huss 5, Chuhan Chung 5, Robert P Myers 5, Rohit Loomba 6
|
|
|
|
|
|
|
|
|
91. | A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis |
|
JHEP Rep. 2022 Aug 23;5(1):100563. doi: 10.1016/j.jhepr.2022.100563. eCollection 2023 Jan.
Stephen A Harrison 1, Peter J Ruane 2, Bradley Freilich 3, Guy Neff 4, Rashmee Patil 5, Cynthia Behling 6, Chen Hu 7, Reshma Shringarpure 8, Brittany de Temple 8, Erica Fong 8, Erik J Tillman 8, Timothy Rolph 8, Andrew Cheng 8, Kitty Yale 8
|
|
|
|
|
93. | A multistakeholder approach to innovations in NAFLD care |
|
Commun Med (Lond)\. 2023 Jan 3;3(1):1. doi: 10.1038/s43856-022-00228-y.
Jörn M Schattenberg 1, Alina M Allen 2, Helen Jarvis 3, Shira Zelber-Sagi 4 5, Ken Cusi 6, John F Dillon 7, Cyrielle Caussy 8 9, Sven M Francque 10 11, Zobair Younossi 12, Naim Alkhouri 13, Jeffrey V Lazarus 14 15 16
|
|
|
94. | Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis |
|
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30.doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
Jingxuan Quek 1, Kai En Chan 1, Zhen Yu Wong 2, Caitlyn Tan 1, Bryan Tan 1, Wen Hui Lim 1, Darren Jun Hao Tan 1, Ansel Shao Pin Tang 1, Phoebe Tay 1, Jieling Xiao 1, Jie Ning Yong 1, Rebecca Wenling Zeng 1, Nicholas W S Chew 3, Benjamin Nah 4, Anand Kulkarni 5, Mohammad Shadab Siddiqui 6, Yock Young Dan 7, Vincent Wai-Sun Wong 8, Arun J Sanyal 6, Mazen Noureddin 9, Mark Muthiah 10, Cheng Han Ng 1
|
|
|
|
|
|
|
97. | Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials |
|
Clin Gastroenterol Hepatol. 2023 Jan;21(1):90-102.e6.doi: 10.1016/j.cgh.2022.01.015. Epub 2022 Jan 22.
Vincent Wai-Sun Wong 1, Won Young Tak 2, George Boon Bee Goh 3, Pin-Nan Cheng 4, Eric J Lawitz 5, Zobair M Younossi 6, Raj Vuppalanchi 7, Ziad Younes 8, Naim Alkhouri 9, Lulu Wang 10, Jialuo Liu 10, Kathryn Kersey 10, Robert P Myers 10, Stephen A Harrison 11, Zachary Goodman 6, Michael Trauner 12, Manuel Romero-Gomez 13, Quentin M Anstee 14, Mindie H Nguyen 15, Takeshi Okanoue 16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
109. | High-Intensity Interval Training is Safe, Feasible and Efficacious in Nonalcoholic Steatohepatitis: A Randomized Controlled Trial |
|
Dig Dis Sci. 2022 Dec 20;1-17. doi: 10.1007/s10620-022-07779-z. Online ahead of print.
Shelley E Keating 1, Ilaria Croci 2 3 4, Matthew P Wallen 5 6, Emily R Cox 7, Moe Thuzar 8 9, Uyen Pham 10 11 12, Gregore I Mielke 13, Jeff S Coombes 2, Graeme A Macdonald 12 14, Ingrid J Hickman 12 15
|
|
|
110. | A practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis |
|
Aliment Pharmacol Ther. 2023 Feb;57(3):304-312. doi: 10.1111/apt.17346. Epub 2022 Dec 13.
Zobair Younossi 1 2 3, Naim Alkhouri 4, Ken Cusi 5, Scott Isaacs 6, Fasiha Kanwal 7, Mazen Noureddin 8, Rohit Loomba 9, Natarajan Ravendhran 10, Brian Lam 2 3, Khalil Nader 11 12, Andrei Racila 2 3 12, Fatema Nader 12, Linda Henry 2 3 12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
118. | Upper gut heat shock proteins HSP70 and GRP78 promote insulin resistance, hyperglycemia, and non-alcoholic steatohepatitis |
|
Nat Commun. 2022 Dec 13;13(1):7715. doi: 10.1038/s41467-022-35310-5.
Giulia Angelini 1 2, Lidia Castagneto-Gissey 3, Serenella Salinari 4, Alessandro Bertuzzi 5, Danila Anello 1, Meenakshi Pradhan 6, Marlen Zschätzsch 7 8, Paul Ritter 9, Carel W Le Roux 10, Francesco Rubino 11, Nicola Basso 3, Giovanni Casella 3, Stefan R Bornstein 12 13, Valentina Tremaroli 6, Geltrude Mingrone 14 15 16
|
|
|
|
|
|
|
|
|
|
|
123. | Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis |
|
Clin Pharmacol Ther. 2022 Dec;112(6):1271-1279. doi: 10.1002/cpt.2745.Epub 2022 Sep 27.
Atoosa Rabiee # 1, Martha D Gay # 2, Narayan Shivapurkar 2, Hong Cao 2, Sandeep Nadella 3, Coleman I Smith 3, James H Lewis 3, Sunil Bansal 2, Amrita Cheema 2, John Kwagyan 4, Jill P Smith 1 2
|
|
|
|
|
125. | Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment |
|
J Clin Transl Hepatol. 2023 Apr 28;11(2):502-515. doi: 10.14218/JCTH.2022.00204.Epub 2022 Dec 23.
Ankoor H Patel 1 2, Dhiraj Peddu 1 2, Sahil Amin 1 2, Mohamed I Elsaid 3 4, Carlos D Minacapelli 1 2, Toni-Marie Chandler 1 2, Carolyn Catalano 1 2, Vinod K Rustgi 1 2
|
|
|
126. | Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey |
|
Curr Probl Cardiol. 2022 Dec;47(12):101333. doi: 10.1016/j.cpcardiol.2022.101333.Epub 2022 Jul 25.
Abdul Mannan Khan Minhas 1, Vardhmaan Jain 2, Muhammad Haisum Maqsood 3, Ambarish Pandey 4, Sadiya S Khan 5, Marat Fudim 6, Gregg C Fonarow 7, Javed Butler 8, Muhammad Shahzeb Khan 9
|
|
|
127. | Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease : A Randomized Controlled Trial |
|
Ann Intern Med. 2023 Jan;176(1):10-21. doi: 10.7326/M22-1787.Epub 2022 Dec 13.
Camilla Dalby Hansen 1, Eva-Marie Gram-Kampmann 2, Johanne Kragh Hansen 3, Mie Balle Hugger 1, Bjørn Stæhr Madsen 3, Jane Møller Jensen 3, Sara Olesen 3, Nikolaj Torp 1, Ditlev Nytoft Rasmussen 3, Maria Kjærgaard 1, Stine Johansen 1, Katrine Prier Lindvig 4, Peter Andersen 3, Katrine Holtz Thorhauge 1, Jan Christian Brønd 5, Pernille Hermann 6, Henning Beck-Nielsen 2, Sönke Detlefsen 7, Torben Hansen 8, Kurt Højlund 2, Maja Sofie Thiele 1, Mads Israelsen 3, Aleksander Krag 9
|
|
|
128. | SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum |
|
J Gastroenterol. 2022 Dec 5;1-19. doi: 10.1007/s00535-022-01932-1.Online ahead of print.
Yoshihiro Kamada 1, Takahiro Nakamura 2, Satoko Isobe 3, Kumiko Hosono 4, Yukiko Suama 5, Yukie Ohtakaki 6, Arihito Nauchi 7, Naoto Yasuda 8, Soh Mitsuta 3, Kouichi Miura 9, Takuma Yamamoto 10, Tatsunori Hosono 11, Akihiro Yoshida 12, Ippei Kawanishi 13, Hideaki Fukushima 14, Masao Kinoshita 15, Atsushi Umeda 16, Yuichi Kinoshita 17, Kana Fukami 18, Toshio Miyawaki 5, Hideki Fujii 19, Yuichi Yoshida 20, Miwa Kawanaka 21, Hideyuki Hyogo 22 23, Asahiro Morishita 24, Hideki Hayashi 25, Hiroshi Tobita 26, Kengo Tomita 27, Tadashi Ikegami 28, Hirokazu Takahashi 29, Masato Yoneda 30, Dae Won Jun 31, Yoshio Sumida 32, Takeshi Okanoue 33, Atsushi Nakajima 30; JANIT Forum
|
|
|
|
|
|
|
131. | Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study |
|
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):120-132.doi: 10.1016/S2468-1253(22)00347-8. Epub 2022 Dec 12.
Rohit Loomba 1, Eric J Lawitz 2, Juan Pablo Frias 3, Grisell Ortiz-Lasanta 4, Lars Johansson 5, Bridgette Boggess Franey 6, Linda Morrow 7, Moti Rosenstock 8, Cynthia L Hartsfield 9, Chao-Yin Chen 9, Leo Tseng 9, R Will Charlton 9, Hank Mansbach 9, Maya Margalit 10
|
|
|
132. | Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial |
|
Cell Metab. 2023 Jan 3;35(1):56-70.e3.doi: 10.1016/j.cmet.2022.12.001. Epub 2022 Dec 21.
Mark Ezpeleta 1, Kelsey Gabel 1, Sofia Cienfuegos 1, Faiza Kalam 1, Shuhao Lin 1, Vasiliki Pavlou 1, Zhenyuan Song 1, Jacob M Haus 2, Sean Koppe 3, Shaina J Alexandria 4, Lisa Tussing-Humphreys 1, Krista A Varady 5
|
|
|
|
|
134. | A nutrigenetic tool for precision dietary management of non-alcoholic fatty liver disease deeming insulin resistance markers |
|
Panminerva Med. 2022 Dec;64(4):485-496.doi: 10.23736/S0031-0808.22.04590-6. Epub 2022 Apr 19.
Nuria Perez-Diaz-Del-Campo 1, Jose I Riezu-Boj 1 2, Bertha A Marin-Alejandre 1, J Ignacio Monreal 2 3, Mariana Elorz 2 4, José I Herrero 2 5 6, Alberto Benito-Boillos 2 4, Fermín I Milagro 1 2 7, Elisabetta Bugianesi 8, Josep A Tur 7 9, J Alfredo Martinez 10 2 7, Itziar Abete 1 2 7, M Angeles Zulet 1 2 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150. | NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity? |
|
Semin Liver Dis. 2022 Nov;42(4):465-474. doi: 10.1055/s-0042-1757712.Epub 2022 Oct 14.
Bing Chen 1, W H Wilson Tang 2, Mario Rodriguez 3, Kathleen E Corey 4, Arun J Sanyal 5, Patrick S Kamath 6, Biykem Bozkurt 7, Hafeez Ul Hassan Virk 8, Gregg S Pressman 9, Jeffrey V Lazarus 10 11, Hashem B El-Serag 12 13, Chayakrit Krittanawong 14
|
|
|
|
|
|
|
153. | Pulse-Echo Quantitative US Biomarkers for Liver Steatosis: Toward Technical Standardization |
|
Radiology. 2022 Nov;305(2):265-276. doi: 10.1148/radiol.212808.Epub 2022 Sep 13.
David T Fetzer # 1, Ivan M Rosado-Mendez # 1, Michael Wang 1, Michelle L Robbin 1, Arinc Ozturk 1, Keith A Wear 1, Juvenal Ormachea 1, Timothy A Stiles 1, J Brian Fowlkes 1, Timothy J Hall 1, Anthony E Samir 1
|
|
|
|
|
155. | Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis |
|
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2451-2461.e3.doi: 10.1016/j.cgh.2021.09.041. Epub 2021 Oct 7.
Anneli Andersson 1, Matt Kelly 1, Kento Imajo 2, Atsushi Nakajima 2, Jonathan A Fallowfield 3, Gideon Hirschfield 4, Michael Pavlides 5, Arun J Sanyal 6, Mazen Noureddin 7, Rajarshi Banerjee 1, Andrea Dennis 8, Stephen Harrison 9
|
|
|
|
|
|
|
|
|
159. | Multiomics study of nonalcoholic fatty liver disease |
|
Nat Genet. 2022 Nov;54(11):1652-1663. doi: 10.1038/s41588-022-01199-5. Epub 2022 Oct 24.
Gardar Sveinbjornsson # 1, Magnus O Ulfarsson # 2 3, Rosa B Thorolfsdottir 2, Benedikt A Jonsson 2, Eythor Einarsson 2, Gylfi Gunnlaugsson 2, Solvi Rognvaldsson 2, David O Arnar 2 4 5, Magnus Baldvinsson 6, Ragnar G Bjarnason 4 7, DBDS Genomic consortium; Thjodbjorg Eiriksdottir 2, Christian Erikstrup 8, Egil Ferkingstad 2, Gisli H Halldorsson 2, Hannes Helgason 2, Anna Helgadottir 2, Lotte Hindhede 8, Grimur Hjorleifsson 2, David Jones 9, Kirk U Knowlton 10, Sigrun H Lund 2, Pall Melsted 2 11, Kristjan Norland 2, Isleifur Olafsson 12, Sigurdur Olafsson 5, Gudjon R Oskarsson 2, Sisse Rye Ostrowski 13 14, Ole Birger Pedersen 14 15, Auðunn S Snaebjarnarson 2, Emil Sigurdsson 16 17, Valgerdur Steinthorsdottir 2, Michael Schwinn 13, Gudmundur Thorgeirsson 2 5, Gudmar Thorleifsson 2, Ingileif Jonsdottir 2 4, Henning Bundgaard 14 18, Lincoln Nadauld 9, Einar S Bjornsson 4 5, Ingrid C Rulifson 19, Thorunn Rafnar 2, Gudmundur L Norddahl 2, Unnur Thorsteinsdottir 2 4, Patrick Sulem 2, Daniel F Gudbjartsson 2 3 20, Hilma Holm 2, Kari Stefansson 21 22
|
|
|
160. | Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease |
|
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2276-2286.e6.doi: 10.1016/j.cgh.2021.10.023. Epub 2021 Oct 21.
Octavi Bassegoda 1, Pol Olivas 2, Laura Turco 3, Mattias Mandorfer 4, Miquel Serra-Burriel 5, Luis Tellez 6, Wilhelmus Kwanten 7, Alexia Laroyenne 8, Oana Farcau 9, Edilmar Alvarado 10, Lucile Moga 11, Elise Vuille-Lessard 12, Jose Ignacio Fortea 13, Luis Ibañez 14, Giulia Tosetti 15, Thomas Vanwolleghem 7, Hélène Larrue 8, Diego Burgos-Santamaría 16, Horia Stefanescu 9, Rafael Paternostro 4, Annalisa Cippitelli 3, Sabela Lens 1, Salvador Augustin 17, Elba Llop 18, Wim Laleman 19, Jonel Trebicka 20, Johannes Chang 21, Helena Masnou 22, Alexander Zipprich 23, Francesca Miceli 3, Georg Semmler 4, Xavier Forns 1, Massimo Primignani 15, Rafael Bañares 14, Angela Puente 13, Annalisa Berzigotti 12, Pierre Emmanuel Rautou 11, Candid Villanueva 10, Pere Ginès 1, J C Garcia-Pagan 2, Bogdan Procopet 9, Cristophe Bureau 8, Agustin Albillos 6, Sven Francque 7, Thomas Reiberger 4, Filippo Schepis 3, Isabel Graupera 24, Virginia Hernandez-Gea 25
|
|
|
|
|
162. | Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH |
|
Hepatol Commun. 2022 Oct 22. doi: 10.1002/hep4.2100. Online ahead of print.
Stephen A Harrison 1, Patrick R Mayo 2, Todd M Hobbs 3, Carlos Canizares 3, Erin P Foster 2, Caroline Zhao 2, Daren R Ure 2, Daniel J Trepanier 2, Jill A Greytok 3, Robert T Foster 2
|
|
|
163. | Weight Loss and Weight Regain in Usual Clinical Practice: Results From the TARGET-NASH Observational Cohort |
|
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2393-2395.e4.doi: 10.1016/j.cgh.2021.01.023. Epub 2021 Jan 21.
Miguel H Malespin 1, Alfred Sidney Barritt 4th 2, Stephanie E Watkins 3, Cheryl Schoen 3, Monica A Tincopa 4, Karen D Corbin 5, Andrea R Mospan 3, Breda Munoz 3, Huy N Trinh 6, L Michael Weiss 7, K Rajender Reddy 8, Rohit Loomba 9, Nyingi Kemmer 1, Anna S Lok 10
|
|
|
|
|
165. | Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality |
|
Front Med (Lausanne). 2022 Oct 6;9:985803. doi: 10.3389/fmed.2022.985803.eCollection 2022.
Cheng Han Ng 1, Jieling Xiao 1, Nicholas W S Chew 1 2, Yip Han Chin 1, Kai En Chan 1, Jingxuan Quek 1, Wen Hui Lim 1, Darren Jun Hao Tan 1, Ryan Wai Keong Loke 1, Caitlyn Tan 1, Ansel Shao Pin Tang 1, Xin Lei Goh 1, Benjamin Nah 3, Nicholas Syn 1, Dan Yock Young 1 3 4, Nobuharu Tamaki 5, Daniel Q Huang 1 3 4, Mohammad Shadab Siddiqui 6, Mazen Noureddin 7, Arun Sanyal 6, Mark Muthiah 1 3 4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
172. | A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease |
|
Endocr Pract. 2022 Oct 20;S1530-891X(22)00648-6. doi: 10.1016/j.eprac.2022.10.007.Online ahead of print.
Clarissa Elysia Fu 1, Cheng Han Ng 2, Jie Ning Yong 1, Kai En Chan 1, Jieling Xiao 1, Benjamin Nah 3, Shirley Huey Shin Bong 4, Khin Maung Win 5, Aung Hlaing Bwa 5, Wen Hui Lim 1, Darren Jun Hao Tan 1, Rebecca Wenling Zeng 1, Nicholas Chew 6, Margaret L P Teng 3, Mohammad Shadab Siddiqui 7, Jude A Oben 8, Arun J Sanyal 7, Vincent Wai-Sun Wong 9, Mazen Noureddin 10, Mark Muthiah 11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
186. | Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent |
|
World J Surg. 2022 Oct 20. doi: 10.1007/s00268-022-06781-w. Online ahead of print.
John V Reynolds 1, Noel E Donlon 2, Jessie A Elliott 2, Brendan Moran 2, Hugo Temperley 2, Tim S Nugent 2, Maria Davern 2, Sinead King 2, Melissa Conroy 2, Joanne Lysaght 2, Narayanasamy Ravi 2, Carmel Ryan 3, Stephen Finn 3, Suzanne Norris 4, Clare L Donohoe 2
|
|
|
187. | Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles |
|
Hepatology. 2022 Oct;76(4):1121-1134. doi: 10.1002/hep.32427. Epub 2022 Mar 17.
Ibon Martínez-Arranz 1, Chiara Bruzzone 2, Mazen Noureddin 3, Ruben Gil-Redondo 2, Itziar Mincholé 1, Maider Bizkarguenaga 2, Enara Arretxe 1, Marta Iruarrizaga-Lejarreta 1, David Fernández-Ramos 2, Fernando Lopitz-Otsoa 2, Rebeca Mayo 1, Nieves Embade 2, Elizabeth Newberry 4, Bettina Mittendorf 5, Laura Izquierdo-Sánchez 6, Vaclav Smid 7, Jorge Arnold 8, Paula Iruzubieta 9, Ylenia Pérez Castaño 10, Marcin Krawczyk 11 12, Urko M Marigorta 2, Martine C Morrison 13, Robert Kleemann 13, Antonio Martín-Duce 14, Liat Hayardeny 15, Libor Vitek 7, Radan Bruha 7, Rocío Aller de la Fuente 16, Javier Crespo 9, Manuel Romero-Gomez 17, Jesus M Banales 6 18, Marco Arrese 8 19, Kenneth Cusi 20, Elisabetta Bugianesi 21, Samuel Klein 5, Shelly C Lu 3, Quentin M Anstee 22 23, Oscar Millet 2, Nicholas O Davidson 4, Cristina Alonso 1, José M Mato 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
201. | Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis |
|
Nutr Metab Cardiovasc Dis. 2022 Oct;32(10):2279-2288.doi: 10.1016/j.numecd.2022.07.001. Epub 2022 Jul 16.
Grazia Pennisi 1, Ciro Celsa 1, Marco Enea 2, Marco Vaccaro 2, Vito Di Marco 1, Carlo Ciccioli 1, Giuseppe Infantino 1, Claudia La Mantia 1, Stefanie Parisi 1, Federica Vernuccio 3, Antonio Craxì 1, Calogero Cammà 1, Salvatore Petta 4
|
|
|
|
|
203. | The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis |
|
J Clin Med. 2022 Sep 8;11(18):5293. doi: 10.3390/jcm11185293.
Gerardo Sarno 1, Luigi Schiavo 2 3, Pietro Calabrese 2 3, Ludwig Álvarez Córdova 4, Evelyn Frias-Toral 5 6, Gabriela Cucalón 7, Eloisa Garcia-Velasquez 8, Vanessa Fuchs-Tarlovsky 9, Vincenzo Pilone 2 3
|
|
|
|
|
205. | Combination Treatment with Hydroxytyrosol and Vitamin E Improves NAFLD-Related Fibrosis |
|
Nutrients. 2022 Sep 14;14(18):3791.
Nadia Panera 1, Maria Rita Braghini 1, Annalisa Crudele 1, Antonella Smeriglio 2, Marzia Bianchi 1, Angelo Giuseppe Condorelli 3, Rebecca Nobili 3, Libenzio Adrian Conti 4, Cristiano De Stefanis 4, Gessica Lioci 5, Fabio Gurrado 5, Donatella Comparcola 6, Antonella Mosca 6, Maria Rita Sartorelli 6, Vittorio Scoppola 1, Gianluca Svegliati-Baroni 7 8, Domenico Trombetta 2, Anna Alisi 1
|
|
|
|
|
207. | Prevalence and predictors of non-alcoholic steatohepatitis in subjects with morbid obesity and with or without type 2 diabetes |
|
Diabetes Metab. 2022 Sep;48(5):101363. doi: 10.1016/j.diabet.2022.101363. Epub 2022 Jun 24.
Erminia Lembo 1, Maria Francesca Russo 1, Ornella Verrastro 1, Danila Anello 1, Giulia Angelini 1, Amerigo Iaconelli 1, Caterina Guidone 1, Gianluigi Stefanizzi 1, Luigi Ciccoritti 1, Francesco Greco 1, Luca Sessa 1, Laura Riccardi 1, Maurizio Pompili 1, Marco Raffaelli 1, Fabio Maria Vecchio 1, Stefan R Bornstein 2, Geltrude Mingrone 3, Amalia Gastaldelli 4, Esmeralda Capristo 1
|
|
|
| | | | | |